D2/D3 dopamine receptor heterodimers exhibit unique functional properties
- PMID: 11373283
- DOI: 10.1074/jbc.M102297200
D2/D3 dopamine receptor heterodimers exhibit unique functional properties
Abstract
Evidence for heterodimerization has recently been provided for dopamine D(1) and adenosine A(1) receptors as well as for dopamine D(2) and somatostatin SSTR(5) receptors. In this paper, we have studied the possibility that D(2) and D(3) receptors interact functionally by forming receptor heterodimers. Initially, we split the two receptors at the level of the third cytoplasmic loop into two fragments. The first, containing transmembrane domains (TM) I to V and the N-terminal part of the third cytoplasmic loop, was named D(2trunk) or D(3trunk), and the second, containing the C-terminal part of the third cytoplasmic loop, TMVI and TMVII, and the C-terminal tail, was named D(2tail) or D(3tail). Then we defined the pharmacological profiles of the homologous (D(2trunk)/D(2tail) and D(3trunk)/D(3tail)) as well as of the heterologous (D(2trunk)/D(3tail) and D(3trunk)/D(2tail)) cotransfected receptor fragments. The pharmacological profile of the cross-cotransfected fragments was different from that of the native D(2) or D(3) receptors. In most cases, the D(3trunk)/D(2tail) was the one with the highest affinity for most agonists and antagonists. Moreover, we observed that all of these receptor fragments reduced the expression of the wild type dopamine D(2) and D(3) receptors, suggesting that D(2) and D(3) receptors can form complexes with these fragments and that these complexes bind [(3)H]nemonapride less efficiently or are not correctly targeted to the membrane. In a second set of experiments, we tested the ability of the split and the wild type receptors to inhibit adenylyl cyclase (AC) types V and VI. All of the native and split receptors inhibited AC-V and AC-VI, with the exception of D(3), which was unable to inhibit AC-VI. We therefore studied the ability of D(2) and D(3) to interact functionally with one another to inhibit AC-VI. We found that with D(2) alone, R-(+)-7-hydroxydypropylaminotetralin hydrobromide inhibited AC-VI with an IC(50) of 2.05 +/- 0.15 nm, while in the presence of D(2) and D(3) it inhibited AC-VI with an IC(50) of 0.083 +/- 0.011 nm. Similar results were obtained with a chimeric cyclase made from AC-V and AC-VI. Coimmunoprecipitation experiments indicate that D(2) and D(3) receptors are capable of physical interaction.
Similar articles
-
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.J Neurochem. 2007 Aug;102(4):1410-24. doi: 10.1111/j.1471-4159.2007.04660.x. Epub 2007 May 26. J Neurochem. 2007. PMID: 17532788
-
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.J Neurochem. 2003 Nov;87(3):631-41. doi: 10.1046/j.1471-4159.2003.02038.x. J Neurochem. 2003. PMID: 14535946
-
Reconstitution of functional dopamine D(2s) receptor by co-expression of amino- and carboxyl-terminal receptor fragments.Eur J Pharmacol. 2000 Jun 2;397(2-3):291-6. doi: 10.1016/s0014-2999(00)00272-7. Eur J Pharmacol. 2000. PMID: 10844126
-
Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: proteins interacting with the third cytoplasmic loop of dopamine D2 and D3 receptors.J Pharmacol Sci. 2010;114(1):25-31. doi: 10.1254/jphs.10r02fm. Epub 2010 Aug 12. J Pharmacol Sci. 2010. PMID: 20716856 Review.
-
Novel dopamine D2 receptor signaling through proteins interacting with the third cytoplasmic loop.Mol Neurobiol. 2012 Feb;45(1):144-52. doi: 10.1007/s12035-011-8227-8. Epub 2011 Dec 20. Mol Neurobiol. 2012. PMID: 22183739 Review.
Cited by
-
Receptor oligomerization: from early evidence to current understanding in class B GPCRs.Front Endocrinol (Lausanne). 2013 Jan 4;3:175. doi: 10.3389/fendo.2012.00175. eCollection 2012. Front Endocrinol (Lausanne). 2013. PMID: 23316183 Free PMC article.
-
G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2.Biomolecules. 2023 Mar 3;13(3):473. doi: 10.3390/biom13030473. Biomolecules. 2023. PMID: 36979407 Free PMC article.
-
Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function.Neuropsychopharmacology. 2006 Nov;31(11):2368-75. doi: 10.1038/sj.npp.1301163. Epub 2006 Jul 19. Neuropsychopharmacology. 2006. PMID: 16855531 Free PMC article. Review.
-
Dopamine receptor-coupling defect in hypertension.Curr Hypertens Rep. 2002 Jun;4(3):237-44. doi: 10.1007/s11906-002-0013-6. Curr Hypertens Rep. 2002. PMID: 12003707 Review.
-
Sex Differences in Dopamine Receptors and Relevance to Neuropsychiatric Disorders.Brain Sci. 2021 Sep 11;11(9):1199. doi: 10.3390/brainsci11091199. Brain Sci. 2021. PMID: 34573220 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases